Week in Review: VC Deal Activity Surges in Q3 2012

Posted by John E. Shave III | October 19, 2012

A couple weeks ago, we covered the NVCA’s third quarter numbers that showed IPOs doubled year over year. Now a new report from CB Insights indicates that the third quarter of 2012 was the busiest quarter for venture capital deal activity since the dot-com era. According to the report, VC firms made a total of 835 investments and deployed $7.5 billion in the third quarter.

The mobile and telecom industry drew the most attention. Deployments to startups in the space grew by 75 percent year over year and 45 percent since the second quarter. And Pennsylvania ranked fourth among the top states for VC deals, based on the dollar amount of deployments, finishing the quarter behind California, Massachusetts, and New York.

Safeguard and our partner companies have also been reaching milestones. Here are some of the highlights:

• BD Diagnostics received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for nasopharyngeal wash, aspirate, and swab in transport media specimens on the BD Veritor System for Rapid Detection of respiratory syncytial virus, which is powered by Alverix technology.
• Beyond.com’s generational survey, conducted with Millennial Branding, was featured in FoxBusiness.com, CIO.com, and U.S. News and World Report.
• Good Start Genetics CEO Don Hardison was featured in a recap of the Consumer Genetics Conference from Reason.com.
• MediaMath was included as a popular demand-side platform for online display advertising in Customer Think.
• Medivo was included in a roundup of healthcare innovators in New York that ran in Forbes. The company was described as a “very interesting model for lab testing revolutionizing the way physicians and patients leverage data to make better decisions leading to improved health.”
• NovaSom launched Accusom Safe Recovery to help anesthesiologists test for sleep apnea before an operation.
• NuPathe received a financial viability exception from NASDAQ. It’s also reducing its workforce to decrease costs and focus on regulatory approval of its migraine patch. That approval, notes Seeking Alpha, could drive NuPathe’s stock to triple in value.
• Putney CEO Jean Hoffman was the subject of a profile by In El Dorado County.
• Safeguard raised 2012 aggregate partner company revenue guidance to a range of $185 million to $190 million, an increase of 33 percent to 37 percent as compared to $139.2 million in 2011. In addition, Safeguard joined a number of companies in supporting the New York Digital Health Accelerator, which announced its inaugural class this week.
• ThingWorx raised Series C financing to strengthen its sales and customer care teams. DowJones Venturewire, Philadelphia Citybizlist, The Philadelphia Inquirer, FinSMEs, and CNN Money covered the news. In addition, ThingWorx was profiled on M2M Evolution, and was selected by OnFarm to power its cloud-based integration and decision system for farmers.

To read more of our Week in Review series, please use the following feed: safeguardscientifics.com/WeekInReview. Have a great weekend!

 

Tags: Alverix, Beyond.com, CB Insights, Good Start Genetics, MediaMath, Medivo, Mobile Technology, NovaSom, NuPathe, Putney, ThingWorx, Venture Capital, Week in Review